Image Source: AsiaOne
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseasesGlobeNewswireJanuary 27, 2020Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in development NIJMEGEN, the Netherlands – Monday January 27, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases.
Source: AsiaOne